Cancer Treat Rep. 1986 Jun;70(6):781-3.

Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.

Cancer treatment reports

E L Cazap, C Gisselbrecht, F P Smith, R A Estevez, C A Alvarez, C Lagarde, A Hannois, S Ahmed, P S Schein, P V Woolley

PMID: 3524826

Abstract

A combination of 5-FU (600 mg/m2 on Days 1 and 8), doxorubicin (40 mg/m2 on Day 1), and cisplatin (75 mg/m2 on Day 1) has been used for treatment of 31 patients with advanced measurable adenocarcinoma of the lung and 35 with gastric cancer. The regimen was given every 4 weeks until disease progression to patients who had not received prior chemotherapy. One complete response occurred in the lung cancer group. Ten of the gastric cancer patients (29%) had partial responses. The median duration of response was 5.5 months and the median survival in responding patients was 10.8 months. Toxicity of the regimen was moderate. We conclude that this combination offers no particular advantages over previously described treatments for these diseases.

Substances

• Doxorubicin
• Cisplatin
• Fluorouracil

MeSH terms

• Adenocarcinoma / drug therapy
• Adenocarcinoma / pathology
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Cisplatin / administration & dosage
• Clinical Trials as Topic
• Doxorubicin / administration & dosage
• Drug Evaluation
• Female
• Fluorouracil / administration & dosage
• Humans
• Lung Neoplasms / drug therapy
• Lung Neoplasms / pathology
• Male
• Middle Aged
• Stomach Neoplasms / drug therapy
• Stomach Neoplasms / pathology

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't
• Research Support, U.S. Gov't, P.H.S.

Grant support

• N01-CO-65332/CO/NCI NIH HHS/United States

LinkOut - more resources

• Medical
  • MedlinePlus Health Information
• Other Literature Sources
  • The Lens - Patent Citations